Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyAjay K. Nooka, Niels W.C.J. van de Donk, Rachel Kobos et al.|Cancer|2023Cited by 87
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, María‐Victoria Mateos et al.|Cancer|2023Cited by 66
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMARakesh Popat, A Krishnan, Saad Z. Usmani et al.|HemaSphere|2022Cited by 3